Zoetis completes acquisition of Jurox Animal Health
“Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners" - Stephanie Armstrong, Zoetis.
Zoetis Ltd has completed its acquisition of Jurox, an Australian animal health firm that provides a wide range of veterinary medicines for livestock and companion animals.
Based in Hunter's Valley, New South Wales, Jurox develops and manufactures more than 150 products in areas such as parasiticides, anti-infectives, anaesthesia, cardiology, and animal reproduction.
Jurox products are currently distributed throughout Australia, the US and more than 20 other countries across the globe and include the surgical induction agent, Alfaxan.
In a press release, Zoetis said the acquisition will bring an increased range of products, with potential for greater global expansion, future growth opportunities and insights into the animal health market.
Commenting on the acquisition, Stephanie Armstrong, Zoetis senior vice president, said: “Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners.
"With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio here in the UK and Ireland.”
Richard Beckwith, Jurox Country manager UK & Ireland, added: “Jurox and Zoetis share similar beliefs about the important role animal health plays for the world, as well as the high standards we must keep to bringing meaningful solutions to our customers.
“We look forward to the future Jurox and Zoetis can build together in the UK and around the world.”
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
